Ardelyx, Inc. (ARDX) Analysts See $-0.40 EPS

April 21, 2018 - By Ellis Scott

Ardelyx, Inc. (NASDAQ:ARDX) Logo

Analysts expect Ardelyx, Inc. (NASDAQ:ARDX) to report $-0.40 EPS on May, 4.They anticipate $0.19 EPS change or 32.20 % from last quarter’s $-0.59 EPS. After having $0.21 EPS previously, Ardelyx, Inc.’s analysts see -290.48 % EPS growth. The stock decreased 1.02% or $0.05 during the last trading session, reaching $4.85. About 412,667 shares traded or 28.30% up from the average. Ardelyx, Inc. (NASDAQ:ARDX) has declined 60.67% since April 21, 2017 and is downtrending. It has underperformed by 72.22% the S&P500.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. The company has market cap of $230.88 million. The Company’s lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It currently has negative earnings. The firm is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications.

Ardelyx, Inc. (NASDAQ:ARDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: